T2 Biosystems (TTOO) announced the sale of four T2Dx Instruments to its European distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrument sale demonstrates commercial expansion to enable increased utilization of the T2Bacteria Panel, the T2Candida Panel, and the T2Resistance Panel. The target hospitals for the new instruments include: Selling a second T2Dx Instrument to a major reference hospital to expand “same store” sales; Selling the first T2Dx Instrument to a hospital in a country for initial market penetration; and Selling two T2Dx Instruments to hospitals in countries that already utilize T2 Biosystems’ products.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TTOO:
- T2 Biosystems achieves milestone with 250,000th novel sepsis test shipped
- T2 Biosystems extends multi-year supplier agreement with Vizient
- T2 Biosystems Advances Sepsis Detection Technology Licensing
- T2 Biosystems announces plans to license technology to expand its leadership
- T2 Biosystems Reports Increased Losses and Cash Crunch